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Abstract

Keywords
Highlights

This paper assesses the influence of a number of factors taken into account when a
brand name drug is replaced by a generic one. It also evaluates responses of health
professionals – physicians and pharmacist—and patients regarding the issue of
switching. We compared and contrasted their responses in order to identify new points
of cooperation for the intended benefit of the patient. Thus, the sample drew from all
three groups, consisting of 50 doctors, 50 pharmacists, and 50 patients. We collected
information regarding the age, residence, income level, and education level for the
patients, and age and experience for the specialists. Based on responses to the survey,
replacing the original medication with a generic one raises many issues, such as lack of
information for the patient and specialist, lack of collaboration between physician and
pharmacist, ineffective communication between specialist and patient, and the influence
of the overall profit motive.



health professionals, pharmacists, brand drugs, generic drugs, patented medicine
✓ This paper concludes that the switch between original medication with a generic one is

rather a necessity than an option.
✓ The pharmaceutical market is currently confronted with some deficiencies related to
information and/ or collaboration between physicians, pharmacists and patients.
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Introduction
The prescribing, dispensing, and purchasing of
drugs are influenced by many factors, and sometimes
attempts to find the best approach can affect the
relationship between physician/pharmacist and patient,
the one who should be the primary beneficiary of health
services (1).
The switch from brand name to generic medication
is increasingly encountered in the current, fluctuating
pharmaceutical environment, one that is continuously
changing due to changing economic and social
conditions. At the same time, many original medications
have lost their patent/license, with a consequential
disappearance of the original medication and increased
reliance upon generic drugs (2).
The original formulation is initially discovered and
developed by a pharmaceutical company, and once
approved for marketing, the company can market and
sell the “original” product exclusively under patent to
recoup funds for research and development and to net
profit.(3). Current studies estimate that bringing a new
drug to market incurs an average cost of 802 million US
dollars over a period of 10 to 15 years (2, 3).
Once the license for a particular product expires, it
is eligible for conversion into a “generic medicine.”
Because the generic drug may differ in color, taste,
shape, inactive ingredients, preservatives, and/ or
packaging, generic manufacturers are usually required
to submit additional documents to the regulating
authority to demonstrate that their drug is manufactured
in compliance with good manufacturing practice, that it
is as pure and stable as the original drug, and that
bioequivalence tests show the same pharmacokinetic
parameters within the body, that is, it must dissolve and
be absorbed at the same rate and to the same extent as
the original product. Specifically, the generic form must
act the same as the patented drug via the same
mechanism, and it must also follow the same pattern of
absorption, distribution, metabolism, and elimination
from the body (3, 4).
However, replacing the original drug with a generic
form is a difficult choice, in some cases, for both the
physician and patient, on the assumption that the generic
drug may not offer the same quality as the original
preparation, as reflected by its lower price. The lower
price, of course, is explained by the fact that the
manufacturer of the generic drug requires no investment
in clinical research and marketing of the new product. In
addition, the fact that many pharmaceutical companies
produce generics leads to competition and lower prices
(3). At times, patients complain of increased incidence

of side effects when switching to a generic drug, and
therapeutic ineffectiveness is often reported by patients
to the physician or the pharmacist. However, the lack of
pharmacovigilance reports and an increased number of
research studies demonstrate no significant differences
in the effectiveness of generic medicines (5, 6).
Ongoing information regarding the comparison of
original and generic drugs is essential for physicians
when choosing to prescribe either the generic vs the
brand name medication, as the physician can take into
account the therapeutic effectiveness/ineffectiveness
and safety profile of each (6). A better understanding of
issues facing the pharmaceutical market, including the
unavailability of the original brand name medications,
and ongoing collaboration between physician and
pharmacist could mitigate patient concern about
acquiring the recommended drug. Other issues such as
stabilizing the patient with a particular treatment,
ensuring adherence to the prescribed medication, and
consideration of the patient’s financial situation should
not be neglected. However, campaigns conducted to
promote various generic drugs, along with close
relationships between the physician/pharmacist and
medical representative, could result in the use of
medications that are not optimal for treating the patient's
needs (7, 8).
Pharmacists are the final link in the chain requiring
well-regulated drug dispensing rules, but the current
financial problems (delayed payments by the National
Health Insurance House or the pharmacy economic
profit) may compromise ethics (1). For example,
patients’ access to information about medicines through
media and their financial limitations may lead them to
pressure their pharmacist, frequently requesting certain
drugs without first consulting with their physician or
health specialist (9).
The aim of this study was the quantitative analysis
of the responses of health professionals—physicians and
pharmacists—and patients on factors that influence the
switch from an original medication to a generic one. We
also conducted a comparative analysis of the responses
of patients, physicians, and pharmacists with the hope of
improving the relationships among these three groups so
as to obtain greater benefit for the patient.

Materials and Methods
The study was conducted in Bucharest and the
surrounding vicinity between January 2016 and May
2016 by distributing questionnaires about generic and
brand name drugs to healthcare professionals and the
non-healthcare general public. The sample included
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three groups: 50 doctors, 50 pharmacists, and 50
Fifty physicians were included in this research.
patients, taking into account various inclusion and In addition to information about age, experience, and
exclusion criteria (Table I).
type of speciality (medical or surgical), eight items were
used to assess their behavior:
Patients
Healthcare professionals
Inclusion criteria
- Age over 18
- Romanian citizen
- People who wanted
to take part in this
study

Exclusion criteria
- Psychiatric disorders
that do not allow the
proper filling of the
questionnaire
- Illiteracy
- People who did not
want to take part in
this research

Inclusion criteria
- People that are practicing
their job (physicians and
pharmacists)
- People who are practicing
medicine in Bucharest or
the counties/ cities/towns
nearby
- People who wanted to take
part in this study
Exclusion criteria
- People who did not want to
take part in this research
- People who do not practice
their profession even if they
have specialized studies

Table I. Criteria for inclusion and exclusion for
the sample in this research

1. The differences between an original drug and a
generic one.
2. The therapeutic efficacy and incidence of adverse
reactions of the original vs. generic drug.
3. The safety profile of a generic drug.
4. The previous medicines given to their patients and
their efficacy.
5. The financial situation of the patient and guidance to
use generic drugs.
6. The relationship with the medical representative and
its influence when choosing to prescribe a certain
medication.
7. The cooperation with the pharmacist when specifying
or switching from the original drug to the generic one
and their knowledge about the lack of medicines in the
market.
8. The previous experience concerning patient attitudes
regarding the use of the generic drug.

The instruments were three different
questionnaires, one for each type of participant:
physician, pharmacist, and patient.
Fifty patients completed a questionnaire which
collected information about age, residence, education
level, and income level, along with 8 additional items
used to assess patient behavior. These included:

Finally,
50
pharmacists
completed
a
questionnaire. In addition to age and experience, seven
items were taken into account to assess their attitudes.
1. The differences between an original drug and a
generic one.

2. The therapeutic efficacy and incidence of adverse
1. The difference between original and generic drug (if reactions of the original vs. generic drug.
they did not know, they were informed when given the 3. Previous experience concerning the patient's
questionnaire).
preferences regarding the use of an original vs. generic
2. The observed differences in health status after drug.
switching from the original drug to the generic one.
4. The importance of the physician's recommendation
3. The effective use of generic drugs in their treatment. when dispensing the medical prescription and the
4. The primary source of information to be taken into previous treatment received by the patient and its
efficacy.
account when purchasing medication.
5. The importance of medical advice when buying 5. The influence of the patient's financial situation when
administering the original medicine and their counseling
medicine.
6. The influence of the drug’s cost when choosing on alternatives to original medicines.
between an original and generic medication.

6. The relationship between the medical representative
7. The problem of failing to purchase a specific drug that and the pharmacy’s financial profit, and influence of
these factors on drug release.
the patient is using in their treatment.
8. Whether the switch from the original prescription to 7. The lack of original drugs in the pharmaceutical
the generic one is based on the recommendation of the market, the impact of this lack, and how the relationship
between the pharmacist and the patient is affected.
specialists or on other sources of information.
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Results
The quantitative analysis of the answers given by
the evaluated people
The patients who answered this questionnaire were
24 to 73 years old (average = 38 years), predominantly
living in an urban environment (84.3%), with a monthly
income between 1000-2000 lei (51%). 64.7% were
university graduates, 17.6% high school graduates,
15.7% postgraduate degree holders, and only 2% college
graduates. Of the total patients, 83.7% knew the
difference between original and generic drugs, and 60%
considered that significant differences appear after
switching from the original drug. 65.3% of patients
found that the generic drug was not as effective as the
brand name drug. 83.7% believed the physician to be the
most important source of information, 51% the
pharmacist, 8.2% other people’s recommendations,
whereas only 2% were influenced by media. Most
patients heeded the guidance the physician's orders
much (50%) to very much (48%), and only 2% of them
less. Patients also considered that the cost of the original
drug was an essential factor when choosing between
original drug and generic drug (58.3%), 54% had
experienced at least once a problem with the purchase of
an original drug and 46% had ever encountered such a
situation. 64.3% indicated that the switch from the
original drug to a generic one was influenced by
pharmacists, 25% by physicians, and 10.7% by other
factors not related to specialists.
The physicians who participated were 25 to 50
years old (average = 32 years), with experience in the
medical field of less than a year (23.1%), between 1 and
5 years (38.5%), 5-10 years (7.7%) and 10 years or more
(30.8%). Their speciality was medical for 84.6% and
surgical for 15.4%. All physicians were familiar with the
concepts of original vs. generic drug and the differences
between them. According to physicians, there are
differences between therapeutic efficacy and incidence
of side effects of the original vs. generic drug, 53.8% of
them responding positively to this item. Also, 61.5%
believed that the original medicine presents a better
safety profile. All physicians took into account the
treatment previously administered to the patient and its
efficacy, but 53.8% did not take into account the
patient’s financial situation when prescribing a new
medicine. Regarding previous experience, 69.2%
answered that patients were reluctant to use the generic
medicine. 76.9% responded that their relationship with
a medical representative did not influence their
prescribing, but 23.1% indicated this as very important.
38.5% of the physicians cooperated with the pharmacist

when they prescribed a patented drug or a generic one,
but a significant percentage of 61.5% did not have any
connections with the pharmacist. 62.5% of the
physicians were aware of the lack of original medicines
in the pharmaceutical marketplace, but this did not
influence them to prescribe generic drugs.
Pharmacists were 24 to 50 years old (average = 28
years), with experience in the pharmaceutical field
mostly between 1 to 5 years (44.9%) or less than one
year (40.8%). Pharmacists understood the concepts of
original and generic drug and the differences between
them. According to 89.9 % pharmacists, there are
differences between the therapeutic efficacy and
incidence of side effects for the original vs. generic drug.
Regarding previous experience, 67.3% of pharmacists
noted that patients prefer the original drug. All surveyed
pharmacists advised patients on alternatives to the
original drugs, but 20.4% did not consider the
recommendations made by the patient’s physician.
95.9% of pharmacists took into account the financial
situation of the patient, and they guided them to
alternatives that they could afford. The previous
treatment used by the patient and its efficacy were
important factors that 98% of the pharmacists
considered when dispensing the medical prescription.
The decision when choosing between an original or
generic medicine was influenced by the relationship
between the medical representative and the pharmacy’s
financial profit only for 18.8% of the pharmacists, while
81.2% ignored this aspect. 51% of pharmacists believed
that the lack of original drugs in the pharmaceutical
market affected their relationship with the patient,
20.4% very much, 20.4% little and 8.2% very little.

Discussions
Comparative analysis of the responses across the
three groups
The surveyed patients lived predominantly in urban
areas. Most were university graduates, a fact that reflects
their knowledge about original vs. generic medications,
as well as their better information about the available
alternatives in the pharmaceutical market. Patients were
concerned about the cost difference between original
and generic medications, believing that generic drugs
were less effective than patented medicine and leading
to a higher frequency of complaints regarding side
effects. This idea was further supported by physicians
and pharmacists who were not always well informed
about current bioequivalence studies, with both groups
believing significant differences exist between the two
types of drugs, with patented medicines having a better
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safety profile than the generic equivalent. Such concerns
by physicians and pharmacists resulted in patients’
reluctance to use a generic drug. Patients were
influenced by the price of drugs, leading them to choose
a generic medicine even when not convinced their
choice was the best option. While this factor was very
important to patients, physicians did not take into
account financial implications when prescribing
medicine, as they, along with pharmacists, generally
believe the original drug to be more effective (10).
Although the main sources of information for the patient
were the physician and the pharmacist, a significant
percentage took into account recommendations made by
other people or by the media (11, 12). Such information
may be inaccurate and could result in pressure on the
physician or pharmacist to presribe less appropriate
medication for the patient’s particular pathology (13, 14,
15). From our results, both physicians and pharmacists
took into account the treatment previously used by the
patient and their adherence to the treatment, the fact that
brings a real benefit for the patient, especially since, as
shown in this study, patients generally listen to the
physician's advice (15).
Lack of original medicines in the current
pharmaceutical market was a concern for all three
groups evaluated (16, 17). Although physicians were
informed about unavailable products, the lack of
collaboration with the pharmacist may result in the
physician’s prescribing a less desired medication, and
thus a significant number of patients face the problem of
being able to afford their treatment. As difficulty
acquiring their medication increases, the patients may
become less confident in the services of the pharmacist.
Pharmacists responded to this dilemma, indicating it can
seriously affect their relationship and collaboration with
the patient (18). Pharmacists advised their patients about
alternatives to the original medicines, and a
representative percentage took into account the
recommendations of the physician (18, 19). Given that
most surveyed patients reported that the switch from an
original drug to a generic was made on the
recommendation of the pharmacists, and given that
pharmacists generally do not collaborate with
physicians, the patient-physician relationship is likely to
be affected (20, 21).

highlights the problems that the pharmaceutical market
is now facing, such as a lack of information for both
patient and specialists, the lack of collaboration between
physician and pharmacist, ineffective communication
between specialists and patients, and even sometimes
the financial benefits to health care professionals that
places the needs of the patients as secondary when in
fact, they should be the primary beneficiaries of
healthcare services.
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